Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia
Authors:
- 18 February 2022
- journal article
- research article
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 56 (3) , 523-529
Abstract
Although the “drug lag”—namely, the delay in drug approval time in Japan relative to the United States and/or European Union (US/EU)—has been shortened for drugs approved in Japan, there remain many new drugs that have been approved in the US/EU, but not in Japan. To assess the possibility of a future drug lag, this study has examined the current lag in drug development in Japan based on “ClinicalTrials.gov” data from multiregional clinical trials (MRCTs) conducted in the US/EU and East Asia. Among 828 MRCTs registered as of April 5th, 2021, the percentage of MRCTs in which Japan participated (jMRCTs) was 57.1%. jMRCTs were common for some diseases such as “nervous system” and “visual system” disorders, but less common for “neoplasm,” infection,” “mental,” and “circulatory” disorders. Regarding the investigational drugs in non-jMRCTs (i.e., MRCTs without Japanese participation) in the latter four therapeutic areas (i.e., neoplasm, infection, mental and circulatory disorders), approximately 80% (313/399) of drugs were not being developed in Japan. Furthermore, many of these drugs were being developed by the top 50 pharmaceutical companies by sales, and the majority would be recognized as a new active ingredient with a new mode of action in Japan. This study has highlighted the possibility of a future drug lag in Japan, especially in the therapeutic areas of neoplasm, infection, mental, and circulatory disorders. Such a lag may arise not only between Japan and the US/EU, but also between Japan and other countries in the East Asian region.Keywords
This publication has 11 references indexed in Scilit:
- Analysis of Pediatric Drug Approval Lag in JapanTherapeutic Innovation & Regulatory Science, 2020
- Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical ConsiderationsJCO Precision Oncology, 2019
- Characteristics and Changes of Pediatric Therapeutic Trials under the Best Pharmaceuticals for Children ActThe Journal of Pediatrics, 2018
- Master Protocols to Study Multiple Therapies, Multiple Diseases, or BothNew England Journal of Medicine, 2017
- ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung CancerClinical Cancer Research, 2015
- Closing the drug lag for new drug submission and review in Japan: An industry perspectiveClinical Pharmacology & Therapeutics, 2015
- Evaluating Many Treatments and Biomarkers in Oncology: A New DesignJournal of Clinical Oncology, 2013
- Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in JapanClinical Pharmacology & Therapeutics, 2013
- Approaches to Japanese Dose Evaluation in Global Drug Development: Factors That Generate Different Dosages Between Japan and the United StatesClinical Pharmacology & Therapeutics, 2011
- Effective Global Drug Development Strategy for Obtaining Regulatory Approval in Japan in the Context of Ethnicity-Related Drug Response FactorsClinical Pharmacology & Therapeutics, 2010